Sofosbuvir as a potential option for the treatment of COVID-19
Keywords:
Sofosbuvir, COVID-19Abstract
Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells. Efficacy and safety of sofosbuvir in treatment of COVID-19 may be considered in future clinical studies.
References
Schinazi, RF, J Shi, and T. Whitaker, Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor. Innovative Drug Synthesis 2016: p. 61-79.
Zuccaro V, et al. PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment? Expert Opinion on Drug Metabolism & Toxicology 2020. 16(2): p. 97-101.
Pockros PJ. Nucleoside/nucleotide analogue polymerase inhibitors in development. Clinics in liver disease 2013. 17(1): p. 105-110.
Hilgenfeld R and M Peiris. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral research 2013. 100(1): p. 286-295.
Elfiky AA, SM Mahdy and WM Elshemey, Quantitative structure‐activity relationship and molecular docking revealed a potency of anti‐hepatitis C virus drugs against human corona viruses. Journal of medical virology, 2017. 89(6): p. 1040-1047.
Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life sciences 2020: p. 117477.
Chen YW, C.-P.B. Yiu, and K.-Y. Wong. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research, 2020. 9.
Xu, H.-T., et al., Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors. Journal of Antimicrobial Chemotherapy 2017. 72(3): p. 727-734.
Lam AM, et al., Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrobial agents and chemotherapy 2012. 56(6): p. 3359-3368.
Fenaux M, et al., Antiviral nucleotide incorporation by recombinant human mitochondrial RNA polymerase is predictive of increased in vivo mitochondrial toxicity risk. Antimicrobial agents and chemotherapy 2016. 60(12): p. 7077-7085.
Thi VLD, et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology 2016. 150(1): p. 82-85. e4.
Netzler NE, et al., Antiviral candidates for treating hepatitis E virus infection. Antimicrobial agents and chemotherapy 2019. 63(6): p. e00003-19.
Wang W, et al. Distinct antiviral potency of sofosbuvir against hepatitis C and E viruses. Gastroenterology 2016. 151(6): p. 1251-1253.
Jiang W, et al. Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system. Antiviral research 2018. 154: p. 51-57.
Dragoni F, et al. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral research 2020: p. 104708.
Bullard-Feibelman KM, et al., The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral research 2017. 137: p. 134-140.
Vicenti, I, et al. Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. SLAS DISCOVERY: Advancing the Science of Drug Discovery 2020: p. 2472555220911456.
Sacramento CQ, et al. The clinically approved antiviral drug sofosbuvir impairs Brazilian zika virus replication. BioRxiv 2016: p. 061671.
Mumtaz N, et al. Cell-line dependent antiviral activity of sofosbuvir against Zika virus. Antiviral research 2017. 146: p. 161-163.
Downloads
Published
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
